靶向药奥希替尼致长QT间期综合征诱发 尖端扭转室速一篇病例报道
A Case Report of Long QT Syndrome and Torsades de Pointes Induced by the Targeted Drug Osimertinib
DOI: 10.12677/acm.2026.162515, PDF,   
作者: 李佳澎, 王 越, 张晓玲, 孙丽霞*：华北理工大学附属医院急诊科，河北 唐山
关键词: 奥希替尼；长QT间期综合征；尖端扭转室速；Osimertinib； Long QT Syndrome； Torsades de Pointes
摘要: 本文总结1例中年非小细胞癌患者住院期间突发TdP。对于高危因素患者，提醒临床医生应早期识别，最大限度地减少此类事件的发生。
Abstract: This case report summarizes a middle-aged non-small cell lung cancer (NSCLC) patient who developed sudden TdP during hospitalization. For high-risk patients, clinicians are reminded to perform early identification to minimize the occurrence of such events.
文章引用：李佳澎, 王越, 张晓玲, 孙丽霞. 靶向药奥希替尼致长QT间期综合征诱发 尖端扭转室速一篇病例报道[J]. 临床医学进展, 2026, 16(2): 1302-1305. https://doi.org/10.12677/acm.2026.162515

参考文献

[1] 郑梅霞. 获得性QT间期延长伴尖端扭转室性心动过速的原因及临床治疗[J]. 中国药物与临床, 2018, 18(11): 1936-1937.
[2] 禹子清, 樊冰. 长QT间期综合征的基因易感性和主要发病机制[J]. 中国临床医学, 2015, 22(3): 442-446.
[3] Roden, D.M. (2019) A Current Understanding of Drug-Induced QT Prolongation and Its Implications for Anticancer Therapy. Cardiovascular Research, 115, 895-903. [Google Scholar] [CrossRef] [PubMed]
[4] Drew, B.J., Ackerman, M.J., Funk, M., Gibler, W.B., Kligfield, P., Menon, V., et al. (2010) Prevention of Torsade de Pointes in Hospital Settings: A Scientific Statement from the American Heart Association and the American College of Cardiology Foundation. Circulation, 121, 1047-1060. [Google Scholar] [CrossRef] [PubMed]
[5] 刘金莎. 药物性长QT间期综合征继发尖端扭转性室速的临床研究[D]: [硕士学位论文]. 长春: 吉林大学, 2013.
[6] Ramalingam, S.S., Vansteenkiste, J., Planchard, D., Cho, B.C., Gray, J.E., Ohe, Y., et al. (2020) Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. New England Journal of Medicine, 382, 41-50. [Google Scholar] [CrossRef] [PubMed]
[7] 汪龙, 张莉, 朱玲娜, 等. 奥希替尼相关心脏毒性的研究进展[J]. 中国医院药学杂志, 2023, 43(13): 1516-1520.
[8] 钱滨滨. 甲磺酸奥希替尼在晚期肺腺癌患者中的应用效果及安全性分析[J]. 系统医学, 2024, 9(21): 155-157.
[9] Cheng, Y., He, Y., Li, W., Zhang, H., Zhou, Q., Wang, B., et al. (2021) Osimertinib versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, a Randomized Study. Targeted Oncology, 16, 165-176. [Google Scholar] [CrossRef] [PubMed]
[10] 陈刚, 张瑞萍, 王红, 等. 阿托品致长Q-T间期诱发尖端扭转性室速1例[J]. 临床医药文献电子杂志, 2019, 6(29): 170.
[11] Saito, Z., Imakita, T., Ito, T., Oi, I., Kanai, O., Fujita, K., et al. (2023) Successful Rechallenge with Osimertinib Following Osimertinib-Induced Ventricular Tachycardia: A Case Report. Case Reports in Oncology, 16, 1100-1106. [Google Scholar] [CrossRef] [PubMed]
[12] 李俊超, 王贺超. 胺碘酮与其他延长QT间期药物合用情况的研究[J]. 中国医药指南, 2017, 15(14): 109-110.
[13] Matsuura, C., Kato, T. and Koyama, K. (2021) Successful Management of Refractory Torsades De Pointes Due to Drug-Induced Long QT Syndrome Guided by Point-of-Care Monitoring of Ionized Magnesium. Cureus, 13, e13939. [Google Scholar] [CrossRef] [PubMed]

为你推荐